Aurobindo Pharma arm's New Jersey unit gets warning letter from USFDA

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

Source: The Economic Times Healthcare and Biotech News - October 22, 2020 Category: Pharmaceuticals Source Type: news